OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
NEW YORK, May 03, 2017 -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held on Friday May 5, 2017 at 8:30am ET to discuss results for the first quarter of 2017 and provide a business outlook for the remainder of the year. Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.
To participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics First Quarter 2017 Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.
TGTX-G
Contact Jenna Bosco Vice President, Investor Relations TG Therapeutics, Inc. Telephone: 212.554.4351 Email: [email protected]
